Postmarket research
Genentech’s hemophilia treatment Hemlibra continues to demonstrate its efficacy in treating patients. New late-stage data presented at World Federation of Hemophilia 2018 World Congress shows the drug significantly reduced treated bleeds in a broad patient population in two separate studies.
At the World Medical Innovation Forum, panelists observed that AI can be used to scour old clinical trial data for new applications and possibly take over part of clinical trials in “virtual” models.
Analysts look at what else AbbVie has in the pipeline after Rova-T Failure.
But the biotech swiftly indicated that it doesn’t expect the halt to last for long.
A Novartis drug approved as a second-line treatment for a blood disorder snagged the FDA’s Breakthrough Therapy Designation as a first-line defense.
Sanofi’s setback could open the door for rival drugmaker Takeda.
Assurex Health, a wholly-owned subsidiary of Myriad Genetics, today announced new positive results for the GeneSight test in patients with Generalized Anxiety Disorder (GAD).
The long term study results were published online in Blood.
Alnylam’s victory with Patisiran in familial amyloid polyneuropathy (FAP) is significant for more than just the company and its patients.
PRESS RELEASES